Mylan and Biocon seek to accelerate introduction of Adalimumab Biosimilar in EUMylan and Biocon have agreed to accelerate introduction of adalimumab biosimilar in Europe through Mylan's in-licensing arrangement with Fujifilm Kyowa Kirin Biologics (FKB). FKB's product is at an advanced stage of review and could potentially obtain approval in Europe in the second half of 2018. We believe that through this arrangement, Mylan could commercialize FKB's Adalimumab in EU around market formation. Biocon retains its economic interest in this arrangement vis-a-vis Mylan in line with its existing global collaboration with Mylan for monoclonal antibodies, said Biocon Spokesperson.

Shares of the company gained Rs 13.85, or 2.26%, to trade at Rs 627.00. The total volume of shares traded was 147,937 at the BSE (11.05 a.m., Thursday).